Phathom Pharmaceuticals, Inc. develops and commercializes treatments for gastrointestinal diseases, with news centered on VOQUEZNA® (vonoprazan), an oral potassium-competitive acid blocker. Company updates commonly cover VOQUEZNA commercialization for GERD, prescription trends, product presentations, clinical and real-world data, and vonoprazan use with antibiotics for H. pylori infection.
Recurring announcements also address financial results, expense discipline, balance-sheet actions, and guidance tied to the company's commercial execution. Phathom's pipeline-related updates include studies evaluating VOQUEZNA in eosinophilic esophagitis and publications or conference presentations involving GERD and non-erosive reflux disease.
Phathom Pharmaceuticals (PHAT) has begun patient screening for a Phase 3 study of as-needed VOQUEZNA for non-erosive GERD. The randomized, double-blind study will compare VOQUEZNA 10 mg with placebo and is expected to enroll approximately 500 adults who report heartburn at least four days per week. It is planned for approximately 80 U.S. sites. The primary measure, assessed at Week 12, is the percentage of heartburn episodes with complete relief within two hours that lasts for 24 hours after dosing.
The study follows previously reported positive Phase 2 results. Phathom expects topline results in the first quarter of 2028. If the Phase 3 study succeeds, the company intends to use it to support a potential submission seeking to add as-needed treatment to VOQUEZNA’s label. VOQUEZNA is already approved for relief of heartburn associated with non-erosive GERD, but the as-needed regimen remains investigational.
Phathom Pharmaceuticals (Nasdaq: PHAT) will participate in two investor conferences in New York in September 2026: the Cantor Global Healthcare Conference on September 9, 2026 with a fireside chat at 10:55 a.m. EDT, and the H.C. Wainwright 28th Annual Global Investment Conference on September 15, 2026 with a fireside chat at 3:30 p.m. EDT. Management will also hold one-on-one meetings at both events. Webcasts and archived recordings will be available for 90 days via the News & Events section of Phathom’s investor website.
Phathom Pharmaceuticals (Nasdaq: PHAT) reported Q2 2026 net revenue of $74.3 million, up 88% year over year and 27% sequentially, driven by VOQUEZNA, with about 325,000 prescriptions in the quarter and 1.7 million cumulatively.
Operating expenses fell to $63.1 million, down 33% versus Q2 2025, yielding near breakeven non-GAAP adjusted net loss of $0.1 million versus $56.5 million a year ago. Cash and equivalents were $182.5 million. Phathom plans a Phase 3 as-needed VOQUEZNA trial in Non-Erosive GERD starting Q4 2026 and expects Phase 2 EoE topline data in Q4 2026. Updated 2026 guidance sets net revenue at $310–325 million and non-GAAP operating expenses at $235–245 million, while maintaining gross margin and gross-to-net assumptions.
Phathom Pharmaceuticals (Nasdaq: PHAT) will host a live webcast on Thursday, July 30, 2026, at 8:00 am EDT to report its second quarter 2026 financial results and provide a business update.
The event will be accessible via the company’s website, with a recording available for 90 days.
Phathom Pharmaceuticals (Nasdaq: PHAT) completed patient enrollment ahead of schedule in its Phase 2 pHalcon-EoE-201 trial of VOQUEZNA (vonoprazan) for eosinophilic esophagitis in adults. The randomized, double-blind, placebo-controlled study enrolled 95 patients at 41 U.S. sites, with 12-week double-blind treatment plus a 12-week VOQUEZNA extension. Topline results are expected in Q4 2026.
Phathom Pharmaceuticals (Nasdaq: PHAT) announced participation in three upcoming investor conferences in May and June 2026.
Management will attend the Craig-Hallum 23rd Annual Institutional Investor Conference on May 28 in Minneapolis, the Jefferies Global Healthcare Conference on June 3 in New York, and the Goldman Sachs 47th Annual Global Healthcare Conference on June 9 in Miami, including fireside chats and one-on-one meetings.
Phathom Pharmaceuticals (Nasdaq: PHAT) reported extensive vonoprazan research at Digestive Disease Week (DDW) 2026, with 31 clinical abstracts, including 28 independent studies and three Phathom-sponsored posters.
Topics covered GERD, H. pylori eradication, safety, post‑ESD care, and a Phase 3 pHalcon‑NERD‑301 analysis honored as a Poster of Distinction. VOQUEZNA® indications and detailed safety information were also highlighted.
Phathom Pharmaceuticals (Nasdaq: PHAT) will present VOQUEZNA® (vonoprazan) clinical and real-world data at Digestive Disease Week® (DDW) 2026 in Chicago, May 2–5. A product theater on VOQUEZNA is scheduled for May 4 at 12:00 PM CDT, and the company will exhibit at booth 2511.
Three poster presentations and post-meeting abstracts will be available on the company publications page.
Phathom Pharmaceuticals (Nasdaq: PHAT) reported Q1 2026 net revenues of $58.3 million, a 104% year-over-year increase, and approximately 1.35 million total VOQUEZNA prescriptions filled to date (as of April 17, 2026). Q1 operating expenses were $61.8 million and non-GAAP operating expenses were $56.2 million. The company reported a Q1 net loss of $30.4 million and non-GAAP adjusted net loss of $14.7 million. Cash and cash equivalents were $180.9 million as of March 31, 2026. Phathom maintained 2026 guidance: net revenues of $320–$345 million, gross-to-net 55–59%, gross margin ~80%, and non-GAAP operating expenses of $235–$255 million, with operating profitability expected beginning in Q3 2026.
Phathom Pharmaceuticals (Nasdaq: PHAT) will report first quarter 2026 financial results and provide a business update via live webcast on Thursday, April 30, 2026 at 8:00 am EDT.
A recording will be available for 90 days. Phathom commercializes vonoprazan as VOQUEZNA products for GERD and H. pylori in the U.S. More information is on the Events & Presentations section of the company website.